David P. Southwell - Jan 18, 2022 Form 4 Insider Report for TScan Therapeutics, Inc. (TCRX)

Role
Chief Executive Officer, Director
Signature
/s/ David P. Southwell
Stock symbol
TCRX
Transactions as of
Jan 18, 2022
Transactions value $
$0
Form type
4
Date filed
1/20/2022, 03:25 PM
Previous filing
Jan 11, 2022
Next filing
May 20, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCRX Stock Option (Right to Buy) Award $0 +275K $0.00 275K Jan 18, 2022 Voting Common Stock 275K $4.85 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option vest over 4 years of service following January 18, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter.